HIGHLIGHTS
- who: Top from the Department of Cancer Biology, Mayo Clinic, Jacksonville, FL, USA have published the article: EGFR as a prognostic biomarker and therapeutic target in ovarian cancer: evaluation of patient cohort and literature, in the Journal: (JOURNAL)
- how: The authors analyzed EGFR staining in the patient cohort via multiple approaches.
- future: Future studies should pursue other staining methods or analysis in combination with other pathway mediators.
SUMMARY
Unfortunately, response to EGFR-targeted tyrosine kinase-based inhibitors (TKIs) in unselected ovarian cancer patient populations has not been encouraging, with . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.